Nuria Romero Laorden-rekin lankidetzan egindako argitalpenak (6)

2020

  1. Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate Cancer

    European Urology

  2. HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies

    Annals of Oncology, Vol. 31, Núm. 9, pp. 1186-1197

  3. Latest progress in molecular biology and treatment in genitourinary tumours

    Clinical and Translational Oncology, Vol. 22, Núm. 12, pp. 2175-2195

2019

  1. Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer

    European Journal of Cancer, Vol. 116, pp. 158-168

  2. Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer

    European Urology, Vol. 75, Núm. 3, pp. 368-373

  3. Prorepair-B: A prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer

    Journal of Clinical Oncology, Vol. 37, Núm. 6, pp. 490-503